Table 2

Risk of Vascular Events by HDL-C According to Lipid-Lowering Treatment

No Lipid-Lowering
(n = 2,153)
Usual Dose Lipid-Lowering
(n = 1,910)
Intensive Lipid-Lowering
(n = 2,046)
All vascular events454262158
 Model 10.95 (0.92–0.97)0.93 (0.89–0.97)0.99 (0.95–1.04)
 Model 20.95 (0.92–0.98)0.93 (0.89–0.97)1.00 (0.96–1.05)
 Model 30.95 (0.92–0.99)0.94 (0.90–0.98)1.02 (0.98–1.07)
 Model 40.96 (0.93–1.00)0.94 (0.90–0.98)1.03 (0.98–1.08)
Myocardial infarction22215779
 Model 10.92 (0.88–0.96)0.90 (0.85–0.95)0.98 (0.91–1.04)
 Model 20.93 (0.88–0.97)0.90 (0.85–0.96)0.98 (0.91–1.05)
 Model 30.93 (0.88–0.97)0.91 (0.85–0.97)0.99 (0.93–1.07)
 Model 40.93 (0.89–0.98)0.91 (0.86–0.97)1.00 (0.93–1.08)
Ischemic stroke1086149
 Model 10.96 (0.90–1.01)0.95 (0.87–1.03)0.98 (0.90–1.06)
 Model 20.95 (0.89–1.02)0.96 (0.88–1.05)0.99 (0.91–1.07)
 Model 30.95 (0.89–1.01)0.97 (0.88–1.06)1.01 (0.93–1.10)
 Model 40.96 (0.90–1.03)0.96 (0.88–1.06)1.00 (0.91–1.09)
Vascular death31213169
 Model 10.95 (0.92–0.99)0.90 (0.85–0.96)1.04 (0.98–1.11)
 Model 20.97 (0.93–1.01)0.91 (0.85–0.97)1.05 (0.98–1.13)
 Model 30.97 (0.93–1.01)0.91 (0.85–0.98)1.07 (1.00–1.15)
 Model 40.98 (0.94–1.02)0.92 (0.86–0.98)1.09 (1.01–1.17)

Values are number of events or hazard ratio (95% confidence interval) per 0.1 mmol/l increase in HDL-C, stratified for no lipid-lowering therapy, usual dose (e.g., pravastatin, atorvastatin 10 mg), or intensive lipid-lowering therapy (e.g., atorvastatin 20 to 80 mg, rosuvastatin). Model 1: Adjusted for age and sex. Model 2: Model 1 + type 2 diabetes mellitus, body mass index, and plasma triglyceride levels. Model 3: Model 2 + smoking and alcohol. Model 4: Model 3 + localization of vascular disease, systolic blood pressure, eGFR, and LDL-C.

Abbreviations as in Table 1.